Autres langues Cognition Therapeutics, Inc.

Actions

CGTX

US19243B1026

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
1,98 ^USD	+1,54%		+2,59%	+7,03%

29/04	Cognition Therapeutics, Inc. Achève le recrutement de l'étude SHIMMER de phase 2 sur le CT1812 dans la démence à corps de Lewy légère à modérée	CI
12/04	Transcript : Cognition Therapeutics, Inc. - Special Call

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	29/04
Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	29/04
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's disease	23/04
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease	22/04
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference	02/04
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024	01/04
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update	26/03
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results	15/03
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results	15/03
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock	14/03
Cognition Therapeutics Prices $11.5 Million Stock Offering	12/03
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock	12/03
Cognition Therapeutics Starts Public Offering; Shares Decline	11/03
Cognition Therapeutics : Results of Operations and Financial Condition - Form 8-K	11/03
Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	11/03
Cognition Therapeutics Announces Proposed Public Offering of Common Stock	11/03
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies	06/03
Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer?s Disease Studies	06/03
Cognition Therapeutics to Present at the TD Cowen Health Care Conference	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cognition Therapeutics, Inc.

Actions

CGTX

US19243B1026

Autres langues

Filtres